Human Metabolomics, North-West University (Potchefstroom Campus), Private Bag x6001, Box 269, Potchefstroom, 2531, South Africa.
Human Metabolomics, North-West University (Potchefstroom Campus), Private Bag x6001, Box 269, Potchefstroom, 2531, South Africa.
Toxicol Lett. 2020 Apr 1;322:104-110. doi: 10.1016/j.toxlet.2020.01.018. Epub 2020 Jan 22.
Isoniazid and rifampicin are well-known anti-mycobacterial agents and are widely used to treat pulmonary tuberculosis (TB) as part of the combined therapy approach, recommended by the World Health Organization. The ingestion of these first-line TB drugs are, however, not free of side effects, and are toxic to the liver, kidney, and central nervous system. These side effects are associated with poor treatment compliance, resulting in TB treatment failure, relapse and drug resistant TB. This occurrence has subsequently led to the recent application of novel research technologies, towards a better understanding of the underlying toxicity mechanisms of TB drugs in humans, mostly focussing on the 2 most important TB drugs: isoniazid and rifampicin. In this review, we discuss the contribution that one such an approach, termed metabolomics has made toward this field, and also highlight the impact that this might have towards the development of improved TB treatment regimens.
异烟肼和利福平是众所周知的抗分枝杆菌药物，被广泛用于治疗肺结核（TB），作为世界卫生组织推荐的联合治疗方法的一部分。然而，这些一线抗 TB 药物的摄入并非没有副作用，对肝脏、肾脏和中枢神经系统有毒性。这些副作用与治疗依从性差有关，导致 TB 治疗失败、复发和耐药性 TB。这种情况随后导致了新型研究技术的应用，以更好地了解人类抗 TB 药物的潜在毒性机制，主要集中在两种最重要的 TB 药物：异烟肼和利福平。在这篇综述中，我们讨论了一种称为代谢组学的方法在这一领域的贡献，并强调了这可能对开发改良的 TB 治疗方案产生的影响。
